BioDrain Medical Ships STREAMWAY(R) Systems Fulfilling Purchase Order From East Coast-Based Hospital
November 15 2011 - 7:00AM
Marketwired
BioDrain Medical, Inc. (OTCBB: BIOR) (OTCQB: BIOR), producer of the
FDA-cleared STREAMWAY System for automated surgical fluid disposal,
announced today that the Company has shipped its patented STREAMWAY
Systems to fulfill a recent multi-unit purchase order totaling
approximately $90,000 from an East Coast-based hospital.
The sale of the majority of these STREAMWAY Systems will be
recognized in BioDrain's fourth quarter revenues. Moreover, the
order represents a one-time and long-term revenue potential, given
the significant consumable sales attributable to the purchase of
each STREAMWAY System.
Kevin Davidson, CEO of BioDrain Medical, commented, "We are very
excited to announce the fulfillment of this order as it
demonstrates BioDrain Medical's continued expansion into surgical
centers and hospitals across the United States. More and more
doctors as well as surgical personnel are becoming aware of and
impressed by the ease of installation and use, and the important
safety, efficiency and cost benefits of our STREAMWAY System.
Surgical personnel are especially pleased with STREAMWAY's
exceptional performance in difficult, high-fluid cases. With this
latest shipment and our recent installations in South Florida and
Minnesota, I am delighted to see that STREAMWAY is gaining traction
in the market for surgical fluid disposal systems."
About BioDrain Medical, Inc.
BioDrain Medical, Inc. has a fully automated, patented and FDA
cleared surgical fluid disposal system that virtually eliminates
operating room workers' exposure to blood, irrigation fluid and
other potentially infectious fluids found in the surgical
environment. Current manual surgical fluid handling methods of
hand-carrying filled surgical fluid canisters and emptying these
canisters is an exposure risk and an antiquated approach to the
handling of surgical fluid waste. BioDrain's STREAMWAY System,
however, fully automates the collection, measurement and disposal
of surgical fluids, resulting in: 1) reducing overhead costs to
hospitals and surgical centers, 2) improving the Occupational State
and Health Association (OSHA) and other regulatory compliance, and
3) improving the efficiency of the operating room (and thereby
making surgeries more profitable).
BioDrain's STREAMWAY System presents a sustainable solution to
fluid disposal in operating rooms. Presently, around 50 million
bloody, potentially disease infected canisters go to landfills in
the United States annually. Moreover, these tainted canisters can
remain in landfills for years. With the installation of BioDrain's
STREAMWAY System, the number of these canisters can be
significantly reduced, making both the operating room and our
environment safer and cleaner. Independent professional sales
representatives that cater to the needs of hospitals and ambulatory
surgical centers across the country are currently representing
BioDrain products. For additional information, please visit:
www.biodrainmedical.com.
Forward-looking Statements:
Certain of the matters discussed in this announcement contain
forward-looking statements that involve material risks to and
uncertainties in the company's business that may cause actual
results to differ materially from those anticipated by the
statements made herein. Such risks and uncertainties include, among
other things, our ability to establish and maintain the proprietary
nature of our technology through the patent process, as well as our
ability to possibly license from others patents and patent
applications necessary to develop products; the availability of
financing; the company's ability to implement its long range
business plan for various applications of its technology; the
company's ability to enter into agreements with any necessary
marketing and/or distribution partners; the impact of competition,
the obtaining and maintenance of any necessary regulatory
clearances applicable to applications of the company's technology;
and management of growth and other risks and uncertainties that may
be detailed from time to time in the company's reports filed with
the Securities and Exchange Commission. This is not a solicitation
to buy or sell securities and does not purport to be an analysis of
the company's financial position. See the company's most recent
Quarterly Report on Form 10-Q and related 8-K filings.
Add to Digg Bookmark with del.icio.us Add to Newsvine
Investor Relations Contact: Stanley Wunderlich Consulting
for Strategic Growth 1 Ltd. Tel: 800-625-2236 ext. 7770 Email:
info@cfsg1.com Or Mr. Kevin Fickle President NUWA Group LLC Tel:
+1-925-330-8315 Email: kevin@nuwagroup.com
Biora Therapeutics (PK) (USOTC:BIOR)
Historical Stock Chart
From Dec 2024 to Jan 2025
Biora Therapeutics (PK) (USOTC:BIOR)
Historical Stock Chart
From Jan 2024 to Jan 2025